Author

Nils-Henning Neß

Observed name: Nils-Henning Ness

Institution: Hexal (Germany)

Observed institutions: Hexal (Germany), University Hospital Carl Gustav Carus

ORCID: 0000-0002-2365-8855

Observed ORCID: 0000-0002-2365-8855

OpenAlex ID: A5005475226

Differentiating societal costs of disability worsening in multiple sclerosis

2019 · Nils-Henning Ness, Dirk Schriefer, et al. · Journal of Neurology · 44

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study

2020 · Nils-Henning Ness, Rocco Haase, et al. · Journal of Medical Internet Research · 24

Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients

2020 · Dirk Schriefer, Nils-Henning Ness, et al. · Therapeutic Advances in Neurological Disorders · 24

Cost of illness in multiple sclerosis by disease characteristics – A review of reviews

2021 · Dirk Schriefer, Rocco Haase, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 22

Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany

2024 · Steffeni Papukchieva, Ann-Sophie Stratil, et al. · Therapeutic Advances in Neurological Disorders · 20

Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis

2020 · Nils-Henning Ness, Dirk Schriefer, et al. · PharmacoEconomics · 14

Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany

2022 · Dominik Koeditz, Juergen Frensch, et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 9

Der Multiple Sclerosis Health Resource Utilization Survey

2021 · Nils-Henning Ness, Dirk Schriefer, et al. · Fortschritte der Neurologie · Psychiatrie · 2

Disparities in patient share and characteristics between disease-modifying therapy-treated and -untreated people with multiple sclerosis in Germany: a claims data analysis from 2017 to 2022

2025 · Ann-Sophie Stratil, Steffeni Papukchieva, et al. · Frontiers in Neurology · 1

Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study

2025 · Hernan Inojosa, Dirk Schriefer, et al. · Journal of Neurology · 1

Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis

2020 · Nils-Henning Ness, Dirk Schriefer, et al. · PharmacoEconomics · 1

Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland

2022 · Dominik Koeditz, Jürgen Frensch, et al. · Nervenheilkunde

Correction to: Differentiating societal costs of disability worsening in multiple sclerosis

2020 · Nils-Henning Ness, Dirk Schriefer, et al. · Journal of Neurology

Works count: 13

Citation count: 162

H-index: 7

I10-index: 6